SCHEMBL3955641

SCHEMBL3955641

CNc1ccc(C(=O)N[C@@H]2C[C@H]3CC[C@@H]2C3)cc1S(=O)(=O)N1Cc2ccccc2C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
PANK3 Q9H999 1/20 0.48
HSD17B10 Q99714 2/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 1/20 0.44
CNR2 P34972 4/20 0.42
TP53 P04637 1/20 0.41
PRSS12 P56730 1/20 0.41
CNR1 P21554 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3946733 1.00 HTT (0.49) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3955645 1.00 HTT (0.49) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL5622986 0.88 CNR2 (0.53) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL5624506 0.88 CNR2 (0.53) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3952718 0.87 CNR2 (0.52) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3957589 0.87 CNR2 (0.52) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3956669 0.87 CNR2 (0.52) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3946727 0.86 HTT (0.48) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3955639 0.86 HTT (0.48) HTTPANK3HSD17B10KDM4EALDH1A1
SCHEMBL3947516 0.85 CNR2 (0.58) HTTPANK3KDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US claimed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US claimed
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US disclosed
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US disclosed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US disclosed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CNR2, TRPV1, CNR1 HTT 1587/4885PANK3 3813/4885HSD17B10 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.